PATENT CLAIM ANALYSIS

Application Number: 15893102
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["424", "139100"]

Abstract:
Provided are methods for clinical treatment of hematological malignancies, such as relapsed or refractory chronic lymphocytic leukemia or lymphoma using an anti-LAG-3 antibody. Particular malignancies include, e.g., chronic lymphocytic leulcemia (CLL), Hodgkin lymphoma (HL), or non-Hodgkin lymphoma (NHL).

Claim (Index 2):
The method of  claim 1 , wherein the anti-LAG-3 antibody is formulated for intravenous administration.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 88.0
- Lexical Diversity: 1.45714
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15021102', '15032919', '14437029', '15703126', '15166114']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7829674206676487
- 35 USC 102 Novelty (BERT): 0.5880434609900597
- Combined Prediction Score: 0.7634750246998898
- Mean Citation Score: 420.279788
- Max Citation Score: 491.10278
- Similarity Product: 463.6675624014557

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test